Tower Research Capital (TRC)’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-95
| Closed | -$357 | – | 6169 |
|
|
2024
Q3 | $357 | Sell |
95
-146
| -61% | -$838 | ﹤0.01% | 5364 |
|
|
2024
Q2 | $2.3K | Buy |
241
+159
| +194% | +$5.36K | ﹤0.01% | 5027 |
|
|
2024
Q1 | $6.22K | Buy |
82
+41
| +100% | +$5.41K | ﹤0.01% | 4409 |
|
|
2023
Q4 | $7.34K | Buy |
+41
| New | +$20.2K | ﹤0.01% | 4624 |
|
|
2023
Q3 | – | Sell |
-2
| Closed | -$10.1K | – | 6331 |
|
|
2023
Q2 | $10.1K | Buy |
+2
| New | +$6.94K | ﹤0.01% | 4176 |
|
|
2023
Q1 | – | Hold |
0
| – | – | – | 5654 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 6515 |
|
|
2022
Q3 | – | Sell |
-2
| Closed | -$7.87K | – | 6604 |
|
|
2022
Q2 | $6K | Sell |
2
-2
| -50% | -$5.21K | ﹤0.01% | 4980 |
|
|
2022
Q1 | $14K | Sell |
4
-4
| -50% | -$17.2K | ﹤0.01% | 3931 |
|
|
2021
Q4 | $48K | Buy |
8
+5
| +167% | +$38.4K | ﹤0.01% | 2797 |
|
|
2021
Q3 | $26K | Hold |
3
| – | – | ﹤0.01% | 3497 |
|
|
2021
Q2 | $29K | Sell |
3
-1
| -25% | -$16.4K | ﹤0.01% | 3544 |
|
|
2021
Q1 | $76K | Buy |
+4
| New | +$46.7K | ﹤0.01% | 2798 |
|
|
2020
Q4 | – | Hold |
0
| – | -$2K | – | 5467 |
|
|
2020
Q3 | – | Sell |
-2
| Closed | -$7.18K | – | 4630 |
|
|
2020
Q2 | $8K | Buy |
+2
| New | +$6.64K | ﹤0.01% | 4130 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 5087 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 5094 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 5158 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 4925 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 5150 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 2885 |
|
|
2014
Q4 | – | Hold |
0
| – | -$12K | – | 4810 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 2717 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 3476 |
|
|
2014
Q1 | – | Hold |
0
| – | -$5K | – | 5033 |
|
|
2013
Q4 | – | Hold |
0
| – | – | – | 3552 |
|
|
2013
Q3 | – | Hold |
0
| – | – | – | 3985 |
|
Other funds holding SEEL
Tower Research Capital (TRC)'s SEEL Position: Q4 2024 in Review
Tower Research Capital (TRC) sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2024, closing a stake of 95 shares — an estimated $357 sold.
Tower Research Capital (TRC) first reported a position in SEEL in Q2 2020 and held it in 12 quarters. The position peaked at $76K in Q1 2021. 2 funds tracked by Wall St. Rank hold SEEL as of Q4 2024.
- Tower Research Capital (TRC) reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Tower Research Capital (TRC) sold 95 Seelos Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $357.
- Tower Research Capital (TRC) first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
- Tower Research Capital (TRC)'s Seelos Therapeutics, Inc. Common Stock position peaked at $76K in Q1 2021.
- 2 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2024.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2024, filed 13 Feb 2025.